UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $304.96, but opened at $281.70. UCB shares last traded at $281.70, with a volume of 1 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on UCBJF. Wolfe Research initiated coverage on shares of UCB in a research note on Monday, February 23rd. They issued an “outperform” rating for the company. Stephens reiterated an “overweight” rating on shares of UCB in a report on Thursday, January 15th. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research report on Monday, February 16th. Barclays restated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of UCB in a research report on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, UCB has a consensus rating of “Buy”.

UCB Trading Down 5.6%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The stock’s 50 day simple moving average is $311.33 and its 200-day simple moving average is $287.98.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.